Trial Profile
Multicentre international study capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms QUASAR-2
- 19 Sep 2016 Primary endpoint (Disease free survival rate at 3 years ) has not been met,according to the results published in the Lancet Oncology
- 19 Sep 2016 Results assessing disease free survival published in the Lancet Oncology (2016).
- 29 Oct 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.